Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery

合作研究：用于增强药物输送的多糖衍生物

• 批准号: 1309218
• 负责人: Lynne Taylor
• 金额: $ 27.5万
• 依托单位: Purdue University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2019-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1309218&HistoricalAwards=false
• 关键词: Collaborative; Research; Polysaccharide; Derivatives; Enhanced

The Biomaterials program in the Division of Materials Research funds the collaborative efforts of researchers at Purdue University and Virginia Polytechnic Institute to develop purpose-designed polymeric crystallization inhibitors to enhance drug solubility, and thereby enhancing the delivery of new drugs with improved therapeutic activity. Oral drug therapy is a key aspect of disease treatment, but many exciting new therapeutic agents fail because of poor water solubility. Such drugs do not reach adequate solution concentrations to be therapeutically effective. Using the amorphous form of the drug, which is a high energy form, can lead to much higher solution concentrations and higher levels of drug delivery to the body. The disadvantage of using amorphous formulations is that they are inherently unstable, frequently crystallizing during production, storage or delivery to the body, and thereby negating any solubility advantage. Although crystallization can be delayed or prevented by incorporating polymeric additives, the range of polymers with suitable properties is limited and the properties of off-the-shelf polymers properties are not optimal. The main aim of this project is to develop synthetic routes in producing novel orally biocompatible polysaccharide amphiphiles designed to inhibit solid and solution phase crystallization of drugs, and at the same time providing desired drug release profiles. Furthermore, the specific structural features governing drug-polymer intermolecular interaction and crystallization inhibition will be elucidated. The technological impact of the project is in creating improved delivery technologies for poorly water-soluble drugs, development of novel drug delivery processes and improved disease treatments. Increasingly, drug developers are interested in solubility enhancement strategies, and these researchers could benefit greatly from the fundamental understanding created by this research. Research findings will be integrated into teaching through undergraduate research activities involving underrepresented minority students, and development of new teaching materials based on this research.Providing patients with new and effective drugs, manufactured as tablets or capsules that can be taken orally, is a key aspect of treating chronic and acute diseases. Unfortunately, many of the new drugs currently being tested have poor solubility in water. The goal of this research is to improve the solubility of new drugs by combining them with novel polymers based on polysaccharides, which are natural, renewable, and abundant materials. These polymers will be synthesized and tested for their ability to improve the solubility and stability of drugs. By properly designing the polymer, it will interact with the drug and the solubility of the drug will be improved because the polymer will prevent it from crystallizing, and thus enhancing its solubility. This research will create improved delivery technologies for poorly water-soluble drugs, if the project is successful. Hence, this research could broadly improve disease treatment, and contribute to success of the drug development process. Research findings will be integrated into teaching through undergraduate research activities, and development of new teaching materials based on this project. Through summer undergraduate research programs at Purdue University and Virginia Tech, students will be recruited and mentored in research activities in the investigators' labs with the active participation of graduate students and faculty members.

材料研究部的生物材料计划资助普渡大学和弗吉尼亚理工学院的研究人员的合作努力，以开发专门设计的聚合物结晶抑制剂，以提高药物溶解度，从而提高具有改善治疗活性的新药的递送。口服药物治疗是疾病治疗的一个关键方面，但许多令人兴奋的新治疗药物由于水溶性差而失败。这样的药物不能达到足够的溶液浓度以在治疗上有效。使用高能量形式的无定形形式的药物可以导致更高的溶液浓度和更高水平的药物递送到身体。使用无定形制剂的缺点是它们固有地不稳定，在生产、储存或递送至身体期间经常结晶，从而否定任何溶解度优势。虽然通过引入聚合物添加剂可以延迟或防止结晶，但是具有合适性能的聚合物的范围是有限的，并且现成聚合物的性能不是最佳的。 该项目的主要目的是开发生产新型口服生物相容性多糖两亲物的合成路线，该两亲物旨在抑制药物的固相和液相结晶，同时提供所需的药物释放曲线。此外，具体的结构特征，药物-聚合物分子间相互作用和结晶抑制将得到阐明。该项目的技术影响是为水溶性差的药物创造改进的输送技术，开发新的药物输送工艺和改进疾病治疗。越来越多的药物开发人员对溶解度增强策略感兴趣，这些研究人员可以从这项研究所创造的基本理解中受益匪浅。研究成果将通过涉及少数民族学生的本科生研究活动和基于该研究的新教材开发融入教学。为患者提供新的有效药物，制成片剂或胶囊，可以口服，是治疗慢性和急性疾病的一个关键方面。不幸的是，目前正在测试的许多新药在水中的溶解度很差。本研究的目标是通过将新药与基于多糖的新型聚合物结合来改善新药的溶解性，多糖是天然的，可再生的和丰富的材料。这些聚合物将被合成并测试其改善药物溶解度和稳定性的能力。通过适当地设计聚合物，它将与药物相互作用，并且药物的溶解度将得到改善，因为聚合物将防止其结晶，从而提高其溶解度。如果该项目成功，这项研究将为水溶性差的药物创造更好的输送技术。因此，这项研究可以广泛地改善疾病治疗，并有助于药物开发过程的成功。研究成果将通过本科生研究活动融入教学，并根据该项目开发新的教材。通过普渡大学和弗吉尼亚理工大学的夏季本科研究项目，学生将在研究生和教职员工的积极参与下，在研究人员的实验室中招募和指导研究活动。